Comparing ultrasound and MRI for liver cancer detection

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to compare the effectiveness of contrast-enhanced ultrasound (CEUS) and abbreviated MRI (AMRI) in detecting early-stage hepatocellular carcinoma (HCC) in patients with indeterminate liver nodules. Participants will undergo both imaging techniques every 3-6 months for up to 24 months, allowing for timely monitoring of any changes in their liver condition. The goal is to determine which imaging method provides better early detection of HCC in this patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Child A or B cirrhosis from any etiology with at least one ILN on 4-phase CT, contrast- enhanced MRI, or contrast enhanced US but without HCC at baseline.
* Adults 18 years old and above

Exclusion Criteria:

* Patients post liver transplantation
* Patients with concurrent or prior HCC (LR-5 or biopsy proven)
* other liver cancer including cholangiocarcinoma
* Patients with any active extra-hepatic malignancy
* Patients with significant comorbidity and limited life expectancy, e.g., stage D congestive heart failure, in whom surveillance is not warranted are also excluded given unlikely clinical benefit
* Patients with contraindication to contrast-enhanced MRI or CEUS, including implanted medical devices that are considered MR unsafe and severe claustrophobia

Where it's running

• University of Michigan
  Ann Arbor, Michigan, United States Recruiting
• University of Texas Southwestern Medical Center
  Dallas, Texas, United States Recruiting

Study contacts

• Study coordinator: Lisa Quirk, MS/MPH
• Email: lisa.quirk@utsouthwestern.edu
• Phone: 214-645-6179

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using contrast-enhanced ultrasound to check Y-90 radioembolization response in liver cancer

  This will test whether contrast-enhanced ultrasound (CEUS) can show treatment response to Y‑90 radioembolization in people with newly diagnosed hepatocellular carcinoma who are scheduled for TARE.

  Recruiting Phase 2 Thomas Jefferson University · Philadelphia, Pennsylvania · NCT07145801

• Blood test for detecting liver cancer and cirrhosis

  This study is testing a new blood test to see if it can help detect liver cancer and cirrhosis in people who have or are being checked for liver issues.

  Recruiting at 7 sites Helio Genomics · Escondido, California and 6 other locations · NCT05199259

• Combining cabozantinib with ipilimumab/nivolumab and TACE for liver cancer treatment

  This study is testing if combining cabozantinib with two immune therapies and a specific type of chemo can help people with liver cancer who can’t have surgery feel better.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT04472767

• Comparing MRI and Ultrasound for Liver Cancer Surveillance in Cirrhotic Patients

  This study is testing whether a new type of MRI can find liver cancer better than regular ultrasound in cirrhotic patients who have trouble with ultrasound imaging.

  Recruiting Concord Repatriation General Hospital · Camperdown, New South Wales and 9 other locations · NCT04455932

• InstaSure Non-Invasive Finger-Press Test for HCC

  This study tests a non-invasive finger-skin test to help identify hepatocellular carcinoma in adults.

  Recruiting Beijing Municipal Administration of Hospitals · Beijing, Beijing Municipality · NCT07848750

• BGB-B2033 vs Sorafenib or Lenvatinib for advanced liver cancer

  This study tests whether the investigational drug BGB-B2033 can help people with advanced hepatocellular carcinoma when given after prior PD-1/PD-L1 therapy, compared with the standard medicines sorafenib or lenvatinib.

  Recruiting at 2 sites Phase 3 BeOne Medicines · South Brisbane, Queensland and 1 other locations · NCT07836530

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.